Zalospirone (WY-47,846) is a selective 5-HT1A partial agonist of the azapirone chemical class.[1][2] It was found to be effective in the treatment of anxiety and depression in clinical trials, but a high proportion of subjects dropped out due to side effects and development was subsequently never completed.[3]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 1-4 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H29N5O2 |
Molar mass | 419.529 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
See also
editReferences
edit- ^ Gleeson S, Barrett JE (October 1990). "5-HT1A agonist effects on punished responding of squirrel monkeys". Pharmacology, Biochemistry, and Behavior. 37 (2): 335–7. doi:10.1016/0091-3057(90)90344-H. PMID 1981937. S2CID 23488390.
- ^ Singh A, Lucki I (April 1993). "Antidepressant-like activity of compounds with varying efficacy at 5-HT1A receptors". Neuropharmacology. 32 (4): 331–40. doi:10.1016/0028-3908(93)90153-T. PMID 8497336. S2CID 38611829.
- ^ Rickels K, Derivan A, Kunz N, Pallay A, Schweizer E (June 1996). "Zalospirone in major depression: a placebo-controlled multicenter study". Journal of Clinical Psychopharmacology. 16 (3): 212–7. doi:10.1097/00004714-199606000-00004. PMID 8784652.